Renasant Corp

RNST

Market cap $3.24B

TUPELO, Miss., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Renasant Corporation (NYSE: RNST) (the “Company”) will announce 2025 third quarter results following the NYSE's closing on Tuesday, October 28, 2025. The Company will hold executive management's quarterly webcast and conference call with analysts on Wednesday, October 29, 2025, at 10:00 AM Eastern Time (9:00 AM Central Time).

TUPELO, Miss., Aug. 18, 2025 (GLOBE NEWSWIRE) -- The board of directors of Renasant Corporation (NYSE: RNST) approved the payment of a quarterly cash dividend of twenty-two cents ($0.22) per share to be paid September 30, 2025, to shareholders of record as of September 16, 2025.

Investors need to pay close attention to RNST stock based on the movements in the options market lately.

Renasant Corporation (NYSE:RNST ) Q2 2025 Earnings Call July 23, 2025 10:00 AM ET Company Participants David L. Meredith - Executive Vice President James C.

While the top- and bottom-line numbers for Renasant (RNST) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Renasant (RNST) came out with quarterly earnings of $0.69 per share, missing the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.69 per share a year ago.

TUPELO, Miss., July 22, 2025 (GLOBE NEWSWIRE) -- Renasant Corporation (NYSE: RNST) (the “Company”) today announced earnings results for the second quarter of 2025.

PASADENA, Calif.--(BUSINESS WIRE)-- #1031exchage--ExchangeRight, one of the nation's leading providers of diversified real estate REIT and DST investments, has announced Renasant Bank's $15 million commitment to ExchangeRight's Essential Income REIT's revolving line of credit, raising the REIT's committed capacity for its Credit Facility from $135 million to $150 million. The credit has been provided by Wells Fargo, Fifth Third, and now Renasant Bank. This closing strategically expands the REIT's credit acces.

BERKELEY, Calif.--(BUSINESS WIRE)--Renasant Bio (Renasant), announced its launch today to advance next-generation disease-modifying treatments for autosomal dominant polycystic kidney disease (ADPKD), the leading genetic cause of end-stage renal failure. Renasant is developing a pipeline of oral small molecule corrector and first-in-class potentiator therapies that directly target the underlying biology of ADPKD, with the goal of restoring the function of key polycystin proteins across multiple.

TUPELO, Miss., July 08, 2025 (GLOBE NEWSWIRE) -- Renasant Corporation (NYSE: RNST) (the “Company”) will announce 2025 second quarter results following the NYSE's closing on Tuesday, July 22, 2025. The Company will hold executive management's quarterly webcast and conference call with analysts on Wednesday, July 23, 2025, at 10:00 AM Eastern Time (9:00 AM Central Time).